CUE News & Events

Cue Biopharma announced that Lucinda Warren, who has served as Cue Biopharma's chief financial and business officer since February and previously as Cue Biopharma's chief business officer from September 2024 until February, has been appointed interim president and CEO. Usman Azam has stepped down as president and CEO and as a director, effective March 26.

Cue Biopharma announced that it will deliver a poster presentation on the company's lead asset, CUE-401, at the World Immune Regulation Meeting, WIRM, being held March 11-14, 2026 in Davos, Switzerland. The presentation will include new in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the treatment of autoimmune and inflammatory diseases. Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein for the Treatment of Autoimmune and Inflammatory Diseases. In CD4+ T effector memory cells, CUE-401 showed TGF-beta-dependent suppression of proinflammatory cytokines, including Th1, Th2, and Th17 responses. In addition, the TGF-beta in CUE-401 prevented activated B cells from differentiating into plasma cells and limited antibody production. In natural killer cells, TGF-beta in CUE-401 counterbalanced the activating effects of interleukin-2, preventing proliferation and upregulation of proinflammatory cytokine production. Together, we believe these results demonstrate that CUE-401 has the potential to provide both short-term control of diverse inflammatory processes via TGF-beta, while also potentially providing durable long-term benefit through the induction and expansion of regulatory T cell responses

Cue Biopharma announced preclinical safety and tolerability data that further supports the preclinical profile of CUE-401, the Company's lead autoimmune asset. "We are very encouraged with this preclinical data, which demonstrated that CUE-401 was well tolerated, and no adverse events were observed," said Usman Azam, M.D., president and chief executive officer of Cue Biopharma. "Data generated from these preclinical studies represent an important addition to the growing evidence supporting the potential of CUE-401 as a first-in-class bifunctional tolerogenic agent for the treatment of autoimmune disease. We look forward to sharing further scientific data and details on the planned investigational new drug (IND) filing for CUE-401 in the upcoming months."